Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

APTUS PHARMA LTD.

NSE : NABSE : 544529ISIN CODE : INE15XJ01010Industry : TradingHouse : Private

BSE129.5119.18 (+17.38 %)

PREV CLOSE ( ) 110.33

OPEN PRICE ( ) 113.98

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 150000

TODAY'S LOW / HIGH ( )112.00 132.39

52 WK LOW / HIGH ( ) 80.8132.39

NSE

This Company is not listed in NSE

Select year

Particulars

Mar 2025

Mar 2024

Mar 2023

Operational & Financial Ratios

Earnings Per Share (Rs)

6.20

26.60

6.48

CEPS(Rs)

1.35

6.75

2.50

DPS(Rs)

0.00

Book NAV/Share(Rs)

13.93

58.88

32.28

Tax Rate(%)

26.11

28.61

34.16

Margin Ratios

Core EBITDA Margin(%)

19.44

8.61

4.40

EBIT Margin(%)

18.69

7.55

3.12

Pre Tax Margin(%)

16.82

6.22

2.10

PAT Margin (%)

12.43

4.44

1.38

Cash Profit Margin (%)

13.49

5.64

2.67

Performance Ratios

ROA(%)

19.48

9.88

3.14

ROE(%)

70.99

58.36

20.06

ROCE(%)

38.22

26.47

13.79

Asset Turnover(x)

1.57

2.23

2.28

Sales/Fixed Asset(x)

16.12

16.77

15.51

Working Capital/Sales(x)

3.26

4.29

5.58

Efficiency Ratios

Fixed Capital/Sales(x)

0.06

Receivable days

65.80

58.41

62.23

Inventory Days

76.71

58.13

59.65

Payable days

53.78

72.69

104.57

Valuation Parameters

PER(x)

0.00

PCE(x)

0.00

Price/Book(x)

0.00

Yield(%)

EV/Net Sales(x)

0.41

0.26

0.14

EV/Core EBITDA(x)

2.06

2.99

3.19

EV/EBIT(x)

2.18

3.46

4.51

EV/CE(x)

0.59

0.66

0.62

M Cap / Sales

0.00

Growth Ratio

Net Sales Growth(%)

37.52

28.49

0.00

Core EBITDA Growth(%)

213.48

153.92

0.00

EBIT Growth(%)

243.52

209.60

0.00

PAT Growth(%)

288.37

310.76

0.00

EPS Growth(%)

-76.70

310.76

0.00

Financial Stability Ratios

Total Debt/Equity(x)

1.49

3.00

2.28

Current Ratio(x)

1.63

2.01

1.81

Quick Ratio(x)

1.05

1.18

1.07

Interest Cover(x)

9.97

5.67

3.06

Total Debt/Mcap(x)